The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Frolov D.V.

Volgograd State Medical University

Petrov V.I.

Volgograd State Medical University

Sukhanova G.A.

National Research Center for Hematology

Linchenko D.V.

Volgograd State Medical University

Nalesnyi A.E.

Volgograd State Medical University

Dyachkova Yu.A.

Volgograd State Medical University

Primary Prevention of Venous Thromboembolism: Current State

Authors:

Frolov D.V., Petrov V.I., Sukhanova G.A., Linchenko D.V., Nalesnyi A.E., Dyachkova Yu.A.

More about the authors

Journal: Journal of Venous Disorders. 2022;16(2): 164‑174

DOI: 10.17116/flebo202216021164

Read: 2613 times

Download PDF (RU)
Contact the author
Table of contents

PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM: CURRENT STATE
PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM: CURRENT STATE

To cite this article:

Frolov DV, Petrov VI, Sukhanova GA, Linchenko DV, Nalesnyi AE, Dyachkova YuA. Primary Prevention of Venous Thromboembolism: Current State. Journal of Venous Disorders. 2022;16(2):164‑174. (In Russ.)
https://doi.org/10.17116/flebo202216021164

 
Подписка 2026 Флебология (Journal of Venous Disorders)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Posi­tive Predictive Value of the Wells Score in Diagnosis of Deep Vein Thro­mbosis: Resu­lts of Bayesian Analysis. Journal of Venous Diso­rders. 2024;(4):274-282
Asplenia — a new cause of thro­mbosis in pregnant women?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):71-76
Resu­lts of application of modi­fied technique of esophageal vari­ces liga­tion in patients with liver cirrhosis combined with hepa­tocellular carcinoma. Endo­scopic Surgery. 2025;(2):17-25
Hemo­stasis diso­rders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(3):39-44
Inno­vative approach for cardiovascular risk predicting by machine learning methods using. Russian Journal of Preventive Medi­cine. 2025;(7):36-42
Effi­cacy and Safety of the Oral Anti­coagulant DIMO­LEGIN Compared to Enoxaparin Sodium for the Prevention of Venous Thro­mboembolism Following Major Joint Replacement Surgery (hip or knee arthroplasty): A Randomized, Double-Blind, Multicenter Trial. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):577-585
Abstract:

The problem of primary prevention of venous thromboembolism (VTE) is currently extremely important throughout the world for various specialists, especially in general surgery, orthopedics, intensive care and therapy. Among all preventive measures, special attention should be paid to anticoagulation in acute phase of disease at the in-hospital stage and early after discharge. This review is devoted to dosage, regimen and duration of anticoagulation depending on the risk of VTEC, efficacy and safety of parenteral and oral anticoagulants. Criteria for anticoagulation dose increment or prolongation of therapy to the outpatient stage are also proposed: high and extremely high level of D-dimer with additional risk factors of VTEC, obesity, reduced motor activity in postoperative period, previous VTEC, additional Caprini scores due to a widespread new coronavirus infection. Conclusions about the need to revise the guidelines on primary prevention of VTEC are made.

Keywords:

venous thromboembolism
primary prevention
direct oral anticoagulants
low molecular weight heparins

Authors:

Frolov D.V.

Volgograd State Medical University

Petrov V.I.

Volgograd State Medical University

Sukhanova G.A.

National Research Center for Hematology

Linchenko D.V.

Volgograd State Medical University

Nalesnyi A.E.

Volgograd State Medical University

Dyachkova Yu.A.

Volgograd State Medical University

Received:

24.10.2021

Accepted:

11.11.2021

Close metadata

References:

  1. Bokerija LA, Zatevahin II, Kirienko AI. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Flebologiya. 2015;9(2):1-52. (In Russ.).
  2. Stoiko YuM, Zamyatin MN. Specific prevention of thromboembolic complications in high and very high-risk patients. Trudnyi patsient. 2007;5(6-7):35-38. (In Russ.).
  3. Efremova OI, Kirienko AI, Lebedev IS, Andriyashkin AV, Grishchenkova AS, Korobushkin GV. Venous Thromboembolism in Patients on Anticoagulant Prophylaxis Having Indications for the Surgical Treatment of Bone and Joint Injury: the Results of a Cross-Sectional Study. Flebologiya. 2018;12(1):12-16. (In Russ.). https://doi.org/10.17116/flebo201812112-16
  4. Tikkinen KAO, Craigie S, Agarwal A, Violette PD, Novara G, Cartwright R, Naspro R, Siemieniuk RAC, Ali B, Eryuzlu L, Johanna Geraci J, Winkup J, Yoo D, Gould MK, Sandset PM, Guyatt GH. Procedure-specific Risks of Thrombosis and Bleeding in Urological Non- cancer Surgery: Systematic Review and Meta-analysis. European Urology. 2018;73(2):242-251.  https://doi.org/10.1016/j.eururo.2017.03.008
  5. Benyo M. Harsfalvi J, Pfliegler G, Molnar Z, Muranyi M, Jozsa T, Flasko T. Present practice of thrombosis prophylaxis of radical prostatectomy in a European country: a Hungarian multicenter study. Urologia Internationalis. 2014;92(3):289-293.  https://doi.org/10.1159/000353918
  6. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population — based case-control study. Archives of Internal Medicine. 2000;160:809-815.  https://doi.org/10.1001/archinte.160.6.809
  7. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V, MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. New England Journal of Medicine. 2013;368(6):513-523.  https://doi.org/10.1056/NEJMoa1111096
  8. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JA, Suh E, Spiro TE, Barnathan ES, Raskob GE. MARINER Investigators. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine. 2018;379(12):1118-1127. https://doi.org/10.1056/NEJMoa1805090
  9. Lobastov KV, Schastlivtsev IV, Porembskaya OYa, Dzhenina OV, Bargandzhiya AB, Tsaplin SN. COVID-19- associated coagulopathy: review of current recommendations for diagnosis, treatment and prevention. Ambulatornaya khirurgiya. 2020;3-4:36-51. (In Russ.). https://doi.org/10.21518/1995-1477-2020-3-4-36-51
  10. Khryshchanovich VYa. Management Principles of Patients with Venous Thromboembolism during the COVID-19 Pandemic. Novosti Khirurgii. 2020;28(3):329-338. (In Russ.). https://doi.org/10.18484/2305-0047.2020.3.329
  11. Kamkin EG. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 12 (21.09.2021). Moscow: Ministerstvo Zdravoohraneniya Rossijskoj Federacii; 2021. Accessed September 25, 2021. (In Russ.). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/075/original/%D0%92%D0%9C%D0%A0_COVID-19_V12.pdf
  12. Mironov SP, Kirienko AI, Skorogljadov AV. Prevention of venous thromboembolic complications in traumatology and orthopedics. Russian clinical guidelines. Travmatologiya i ortopediya Rossii. 2012;1(63):1-24. Accessed September 2, 2021. (In Russ.). https://www.tfoms.e-burg.ru/upload/expert_files/tromboembolism_profilaxys.pdf.
  13. Yavelov IS. Anticoagulant therapy for the prevention and treatment of venous thromboembolism. Flebologiya. 2010;4(4):4-14. (In Russ.).
  14. Zamyatin MN, Stoyko YuM, Petrova NV. The pathophysiological basis of a choice of anticoagulants for prophylaxis and treatment of thrombotic complicationts in a multidisciplinary hospital. Klinicheskaya patofiziologiya. 2017;22(1):3-10. (In Russ.).
  15. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450-2458. https://doi.org/10.1182/blood-2014-07-590323
  16. Li G, Holbrook A, Jin Y, Zhang Y, Levine M, Mbuagbaw L, Witt D, Crowther M, Connolly S, Chai-Adisaksopha C, Wan Z, Cheng J, Thabane L. Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. Eur J Epidemiol. 2016;31(6):541-561.  https://doi.org/10.1007/s10654-016-0178-y
  17. Kasimova AR, Bozhkova SA. The Application of Different Groups of Medications for the Pharmacological Prevention of Thromboembolism After Major Orthopaedic Surgery in the Clinical Practice. Flebologiya. 2018;12(4):306-313. (In Russ.). https://doi.org/10.17116/flebo201812041306
  18. Zaklyakova LV, Ovsyannikova EG, Kitiashvili IZ, Zaklyakov KK, Orlenko OA, Burtseva NB, Khaymina TD. Heparin, actual issues of therapy. Astrahanskij medicinskij zhurnal. 2018;13(1):14-22. (In Russ.).
  19. Yavelov IS. Low-molecular-weight heparin preparations: basic properties and possibilities of creating analogs. Klin farmakol i terap. 2010;19(1):56-63. (In Russ.).
  20. Gelfand BR, Kirienko AI, Protsenko DN, Ignatenko OV, Gelfand EB. «EVIDANCE» — Russian national epidemiological study. Anesteziologija i renimatologija. 2014;59(5):33-36. (In Russ.).
  21. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M, Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin Dalteparin: an assessment of safety and pharmacodynamics: The DIRECT study. Arch Intern Med. 2008;168(16):1805-1812. https://doi.org/10.1001/archinte.168.16.1805
  22. Register of medicines of Russia. Official Website. Accessed September 25, 2021. (In Russ.). https://www.rlsnet.ru/
  23. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama SM. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):227-277.  https://doi.org/10.1378/chest.11-2297
  24. Balibrea JL, Altimiras J, Larruzea I, Gómez-Outes A, Martínez-González J, Rocha E, Bemiparin Cooperative Study Group in Surgery for Cancer. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int J Surg. 2007;5(2):114-119.  https://doi.org/10.1016/j.ijsu.2006.07.005
  25. Kuznetsov MR, Marchenko IP, Fedorov EE. Prevention of venous thromboneembolic events in surgery. Ambulatornaya khirurgiya. 2018;1-2(69-70): 20-25. (In Russ.). https://doi.org/10.21518/1995-14772018-1-2-20-25
  26. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604.  https://doi.org/10.1056/NEJMoa0810773
  27. Stoiko YuM, Kartasheva ED. Choosing an anticoagulant in a patient with venous thromboembolic complications. Ambulatornaya khirurgiya. 2016;1-2(61-62):29-34. (In Russ.).
  28. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967-977.  https://doi.org/10.2147/TCRM.S84210
  29. Beyer-Westendorf J, Lützner J, Donath L, Tittl L, Knoth H, Radke OC, Kuhlisch E, Stange T, Hartmann A, Günther KP, Weiss N, Werth S. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Thromb Haemost. 2013;109(1):154-163.  https://doi.org/10.1160/TH12-07-0510
  30. Rath NK, Goodson MW, White SP, Forster MC. The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement. Knee. 2013;20(6):397-400.  https://doi.org/10.1016/j.knee.2013.01.006
  31. Efimov EV. Prevention of pulmonary embolism in high-risk patients. Lechashchii vrach. 2016;12(2). Accessed September 2, 2021. (In Russ.). https://www.lvrach.ru/2016/02/15436396
  32. Almarshad FM, Almegren M, Alshuaibi T, Alobaodi N, Almutawa A, Basunbl H, Al Gahtani F, Al Rawahi B. Thromboprophylaxis after bariatric surgery. Blood research. 2020;55(1):44-48.  https://doi.org/10.5045/br.2020.55.1.44
  33. Farraj M, Bramnik Z, Kvasha A, Merie M, Sbeit W, Farraj S, Waksman I. Is LMWH Sufficient for Anticoagulant Prophylaxis in Bariatric Surgery? Prospective Study. Obes Surg. 2017;27(9):2331-2337. https://doi.org/10.1007/s11695-017-2638-1
  34. Brotman DJ, Shihab HM, Prakasa KR, Kebede S, Haut ER, Sharma R, Shermock K, Chelladurai Y, Singh S, Segal JB. Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis. JAMA Surg. 2013;148(7):675-686.  https://doi.org/10.1001/jamasurg.2013.72
  35. Alsina E, Ruiz-Tovar J, Alpera MR, Ruiz-García JG, Lopez-Perez ME, Ramon-Sanchez JF, Ardoy F. Incidence of Deep Vein Thrombosis and Thrombosis of the Portal — Mesenteric Axis After Laparoscopic Sleeve Gastrectomy. J Laparoendosc Adv Surg Tech. 2014;24(9):601-605.  https://doi.org/10.1089/lap.2014.0125
  36. Khitaryan AG, Shatov DV, Orekhov AA, Vachilya TP, Miziev IA, Khatsiev BB. A new approach to effective prevention of venous thromboembolism in bariatric surgery: a single-center experience. Flebologiya. 2020;14(4):287-295. (In Russ.). https://doi.org/10.17116/flebo202014041287
  37. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204. https://doi.org/10.1200/JCO.2013.49.1118
  38. Watson HG, Keeling DM, Laffan M, Tait RC, Makris M, British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170(5):640-648.  https://doi.org/10.1111/bjh.13556
  39. Mandalà M, Falanga A, Roila F, ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(suppl 6):vi85-vi92. https://doi.org/10.1093/annonc/mdr392
  40. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O’Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH, CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):720-728.  https://doi.org/10.1056/NEJMoa1814630
  41. Khorana AA, Weitz JI. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. Thromb Haemost. 2017;118(S 01):23-33.  https://doi.org/10.1160/TH17-09-0681
  42. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Gal GL, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS, AVERT Investigators. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;380(8):711-719.  https://doi.org/10.1056/NEJMoa1814468
  43. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AWA, Tripodi A, PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355(17):1780-1789. https://doi.org/10.1056/NEJMoa054444
  44. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393. https://doi.org/10.1093/eurheartj/ehy136
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.